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Invariant natural killer T (iNKT) cells are innate-like lymphocytes
recognizing CD1d-restricted glycolipid antigens, such as -
galactosylceramide (GC). We assessed whether iNKT cells help B
lymphocyte responses and found that mice immunized with pro-
teins and GC develop antibody titers 1–2 logs higher than those
induced by proteins alone. Activation of iNKT cells enhances
protection against infections such as influenza and elicits higher
frequencies of memory B cells and higher antibody responses to
booster immunizations. Protein vaccination withGC, but not with
conventional adjuvants, elicits IgG responses in mice lacking MHC
class II molecules, demonstrating that iNKT cells can substitute for
CD4 T cell help to B cells. Interestingly, the decay of circulating
antibodies is faster in mice lacking iNKT cells. These findings point
to a homeostatic role for iNKT cells on critical features of the
antibody response such as immunity and B cell memory.
-galactosylceramide  B cell memory  protein vaccination 
serological memory
The help of CD4 T cells to B cells in secondary lymphoidorgans leads to naı¨ve B lymphocyte activation that results in
the generation of both long-lived plasma cells (PCs) andmemory
B cells expressing high-affinity, somatically mutated, class-
switched Ig. This interaction requires presentation of processed
antigens by B cells to CD4 T cells, signaling by costimulatory
molecules such as CD40 on B cells, and production of cytokines
by activated T cells (1).
It has been shown that generation of T-dependent antigen-
specific antibody responses also requires the participation of
molecular and cellular components of the innate immune sys-
tem. For instance, Toll-like receptors are molecules of the innate
immune system that sense microbial infection and induce both
dendritic cell maturation (2, 3) and direct B cell activation (4, 5).
Similarly, NK cells, which are effector cells of the innate immune
system, can activate B cells to produce IgG (6, 7).
Invariant natural killer T (iNKT) cells express a peculiar
TCR chain encoded in mice and humans by the homologue
invariant V14-J18 and V24-JQ rearrangements, respec-
tively. The invariant TCR chain pairs with variable TCR
chains that, however, use a restricted repertoire of V regions,
comprising V8.2, V7, and V2 in mice and V11 in human (8,
9). This TCR recognizes CD1d (10, 11), a non-MHC-encoded
class I-like molecule expressed on cells of haematopoietic (e.g.,
monocytes, dendritic cells, B and T lymphocytes), and nonh-
aematopoietic (e.g., thymic epithelial cells, keratinocytes, hepa-
tocytes) origin (12, 13). iNKT cells can be activated by exogenous
glycosphingolipids, such as -galactosylceramide (GC, isolated
from marine sponges) (14, 15), -glycuronosylceramides, or
diacylglycerol (isolated from the Gram-negative bacteria Sphin-
gomonas and Borrelia burgdorferi spirochete, respectively), which
specifically bind CD1d (16–19). Furthermore, iNKT cells exhibit
a substantial intrinsic autoreactivity that can be explained with
the CD1d-restricted recognition of mammalian endogenous
(glyco)lipids such as isoglobotrihexosylceramide (iGB3) (20).
iNKT cells are regarded as actors of the innate immune system
because they display a constitutive effector-memory phenotype
with immediate effector functions and express a semiinvariant T
cell receptor (TCR) together with NK cell receptors (21–23).
In vivo administration of GC into mice and human rapidly
activates iNKT cells to release T helper 1 (Th1) and Th2
cytokines that in turn contribute to the activation of NK cells,
dendritic cells, and T lymphocytes (13, 24). Indeed, GC-
activated iNKT cells have been reported to potentiate T cell
responses against infectious agents (25–27) or tumors (28–30).
It has been demonstrated that administration of GC alone in
mice results in increased levels of serum IgE (31). We have
previously shown that human iNKT cells efficiently help B cell
proliferation and antibody production in a CD1d-restricted
manner in vitro (32).
Here, we have addressed whether iNKT cells can help specific
antibody responses induced in mice by protein subunit vaccines.
We found that coadministration of GC and protein vaccines
significantly enhances critical features of the antibody response,
such as protection from infections and B cell memory.
Results
Activation of iNKT Cells Enhances Antibody Responses to Protein
Antigens in Vivo. We have recently demonstrated that human
iNKT cells can help B lymphocytes to proliferate and produce
immunoglobulins in vitro. To determine the in vivo relevance of
this finding, we immunized C57BL/6 mice i.m. with bacterial
[tetanus toxoid (TT) and diphtheria toxoid (DT)] or viral (the
hemoagglutinin/neuroaminidase subunits from the human
A/Panama/2007/99 influenza virus, H3N2) proteins with or
without the iNKT cell-specific glycolipid GC, and assessed
serum titers of protein-specific antibodies at various time points.
Fig. 1A shows that, independently of the antigen used, mice
immunized with proteins and GC displayed antibody titers 1–2
logs higher than titers of mice immunized with proteins alone.
Comparable results were obtained in BALB/c, CD1, and C3H/
HeJ mice or when immunizations were performed i.m., i.p., s.c.,
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or i.v., indicating that the adjuvant activity is not strain-specific
and is independent of Toll-like receptor 4 activation and largely
independent of the route of administration [see supporting
information (SI) Fig. 7 and SI Fig. 8]. Unlike previous reports
(33), we never observed consistent antibody responses after
intranasal immunization with proteins admixed with GC (see
SI Fig. 8).
To prove that the adjuvant activity of GC was caused by
iNKT cell activation, mice lacking iNKT cells (J18/) and their
WT littermates (J18/) were immunized with H3N2 alone or
GC. As shown in Fig. 1B, all mice immunized with H3N2 alone
developed comparable antibody responses, regardless of the
presence of iNKT cells. However, when immunization was done
with H3N2 plus GC, mice bearing iNKT cells showed a
significant enhancement in titers of H3N2-specific antibodies,
whereas mice lacking iNKT cells failed to do so. Comparable
results were obtained in mice lacking CD1d (CD1d/), the
restriction element that presents GC to iNKT cells (data not
shown).
To compare GC activity with that of more conventional adju-
vants, mice were immunized with increasing doses of TT given
alone, admixed with GC, or with an optimal dose of one of the
following adjuvants: complete Freund’s adjuvant (one of the stron-
gest adjuvants used in mice; ref. 34), CpG (a strong Th0/Th1
immune-stimulator currently being tested in human; ref. 35), and
Alum (an adjuvant licensed for human use, considered a Th0/Th2
inducer; ref. 36). As shown in Fig. 2A, GC is overall as potent as
the best benchmark adjuvants in helping Ig production, which is
particularly evident at the lowest antigen dose. Moreover, GC
does not polarize the Th response but elicits a ‘‘balanced Th0’’
production of IgG1 and IgG2a antibodies.
An important feature for an adjuvant is that it can be used for
several immunizations. As it has been reported that iNKT cells
are hyporesponsive to a second systemic injection of GC (37,
38), we investigated whether repeated injections of GC would
affect the adjuvant activity of iNKT cells in vivo. To this aim,
mice were immunized with H3N2 and 0.1 g of GC followed
2 weeks later by another immunization with TT and 0.1 g of
GC. The results in SI Table 1 show that IgG titers to TT in
BALB/c mice immunized i.m. with TT and GC are significantly
higher than in mice immunized with TT alone, regardless of the
previous immunization with an unrelated protein (H3N2) and
GC. This finding demonstrates that repeated i.m. injections of
low doses (0.1 g) of GC do not result in the iNKT cell
hyporesponsiveness observed in mice that had received system-
ically high doses (1–25 g) of GC (37, 38).
Finally, we assessed whether antibody responses to protein
antigens could develop with the help of iNKT lymphocytes in the
absence of conventional CD4 helper T cells, a situation where
other adjuvants fail to help antibody responses. Thus, mice that
lack MHC class II molecules (MHC-II/) were immunized
twice with H3N2, given alone, with Alum, or with GC. As
expected,MHC-II/ mice immunized with H3N2 alone or with
Alum did not develop antigen-specific antibodies (Fig. 2B).
Instead, MHC-II/ mice immunized with H3N2 plus GC
remarkably mounted detectable H3N2-specific IgG antibodies.
Fig. 1. Activated iNKT cells help antibody responses to bacterial and viral
proteins in vivo. Groups of four to six mice were immunized twice (arrows)
with the indicated proteins, given alone () or with GC (■). (A) GMTs (and
95% C.I.) of circulating antigen-specific antibodies in C57BL/6 WT mice immu-
nized with TT or DT with or without GC. (B) GMTs and 95% C.I. of antigen-
specific antibodies in sera from C57BL/6 mice bearing (J18/) or lacking
(J18/) iNKT cells, immunized with H3N2 or H3N2 plus GC. Results are from
one experiment of six (TT), two (DT), or four (H3N2). Asterisks indicate statis-
tically different values between mice immunized with the protein alone and
mice immunized with the protein and GC (*, P  0.05; **, P  0.01).
Fig. 2. Activated iNKT cells help T-dependent antibody responses like conventional adjuvants and can substitute for MHC-II-restricted T lymphocytes. (A) IgG1
and IgG2a subclass distribution of circulating TT-specific antibodies in C57BL/6 mice 2 weeks after two immunizations with increasing doses of TT alone, TT plus
GC, TT plus Alum, TT plus CpG, TT plus complete Freund’s adjuvant (CFA)/incomplete Freund’s adjuvant (IFA). (B) GMTs and 95% C.I. of H3N2-specific IgG in sera
from C57BL/6 MHC-II/ mice 2 weeks after two immunizations with H3N2 alone, H3N2 plus Alum, or H3N2 plus GC. Results are from one experiment
representative of three, in which 3–10 mice per group were tested. Asterisks indicate statistically different values between mice immunized with the protein alone
and mice immunized with the protein and the given adjuvant (*, P  0.05; **, P  0.01).
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Altogether, these results demonstrate that iNKT cells acti-
vated in vivo by GC potentiate antibody responses to protein
antigens in a manner comparable to that of the best conventional
adjuvants. Furthermore, at a variance with conventional adju-
vants, GC does not require MHC-class II–restricted CD4 T
lymphocytes to elicit IgG responses.
iNKT Cells Help Humoral Immunity.Having demonstrated that GC
enhances antibody responses to pathogen-derived proteins, we
addressed the quality of the response and asked whether these
antibodies were capable of protecting mice from infections. To
this end, we compared the adjuvant effect of GC with that of
MF59 (a squalene-in-oil emulsion adjuvant licensed for routine
use in human with flu vaccines; ref. 39) in a mouse model of
vaccination against influenza virus infection, where protection
depends mainly on the induction of neutralizing antibodies
against the hemoagglutinin/neuroaminidase subunits (40).
Three groups of mice were immunized twice with H1N1 proteins
(from the human influenza virus A/NewCaledonia/20/99) alone,
with H1N1 plus MF59, or with H1N1 plus GC. Two weeks after
the last immunization, mice were challenged with 100 LD50 of
the mouse-adapted A/WS/33(H1N1) flu virus, and their survival
was followed up for 14 days. As shown in Fig. 3A, 1 day before
challenge, mice immunized with H1N1 and either GC or MF59
exhibit comparable antibody titers, which were significantly
higher than those displayed by mice immunized with the protein
alone. Consequently, 2 weeks after virus challenge, 80% of mice
immunized with H1N1 plus GC, and 100% of those immunized
with H1N1 plus MF59 were alive, whereas only 10% of mice
immunized with H1N1 alone survived (Fig. 3B).
Altogether, these results demonstrate that GC-dependent
iNKT cell activation enhances the efficacy of vaccines against
infectious diseases.
iNKT Cells Spontaneous Activity Contributes to Sustain Serological
Memory. To investigate the role of iNKT cells in the regulation
of serological memory, we assessed the persistence of circulating
antigen-specific antibodies in mice bearing (J18/) or lacking
(J18/) iNKT cells immunized twice with a protein antigen
alone (H3N2). In both groups of mice, titers of antigen-specific
antibodies peaked at comparable levels 2 weeks after the last
immunization. However, the decay of antibody titers was faster
in J18/ mice as compared with J18/ mice (Fig. 4). As this
phenomenon was observed in the absence of exogenous GC, we
conclude that iNKT cell-dependent spontaneous activity (18, 20)
should influence the survival of PCs, which is the critical
parameter regulating the half-life of circulating antibodies in
mice (41). Since starting from 3 weeks after the second immu-
nization with H3N2 alone the number of H3N2-specific PCs in
the bone marrow (BM) was below the detection limit of ELIS-
POT assays, this conclusion could not be formally demonstrated
(data not shown).
All together, these results demonstrate that iNKT cells play a
homeostatic role in maintaining circulating antibody levels and
suggest that they may do so by regulating PCs survival.
iNKT Cell Activation by GC Enhances Recall Antibody Responses and
Contributes the Maintenance of B Cell Memory.A key feature of the
adaptive immune system is the ability to mount a quicker recall
response to previously encountered antigens. To assess whether
iNKT cell activation by GC influenced the recall antibody
response, mice were immunized twice, at weeks 0 and 2, with
H3N2 or with H3N2 plus GC. A third (recall) immunization
with H3N2 alone was then given to all mice at week 30. Fig. 5A
shows that, after the first two doses, antibody titers in mice
immunized with H3N2 plus GC were significantly higher than
those from mice injected with H3N2 alone. In the following
weeks, H3N2-specific antibodies decayed over time with similar
Fig. 3. iNKT cell activation enhances the protective efficacy of a subunit
influenza vaccine. (A) GMTs and 95% C.I. of circulating H1N1-specific IgG in
C57BL/6 mice 2 weeks after two immunizations with H1N1 alone, H1N1 plus
GC, or H1N1 plus MF59. (B) Survival curves of the mice described in A and
control mice injected with PBS alone after intranasal challenge with the
influenza virus A/WS/33. Results are from one experiment representative of
two in which 10 mice per group were tested. Asterisks indicate statistically
different values between mice immunized with H1N1 alone and mice immu-
nized with H1N1 plus GC or H1N1 plus MF59 (*, P  0.05; **, P  0.002).
Fig. 4. iNKT cells sustain serum antibody titers. Decay of serum antibodies in
C57BL/6 mice bearing (J18/) or lacking (J18/) iNKT cells immunized
(arrows) with H3N2 alone. Results are from one experiment representative of
three in which five mice per group were tested. Asterisks indicate statistically
different values (P  0.03) between the two groups of mice.
Fig. 5. Activated iNKT cells enhance B cell memory. (A) GMTs and 95% C.I.
of H3N2-specific antibodies in C57BL/6 WT mice before and after two immu-
nizations (arrows) with H3N2 or H3N2 plus GC and a subsequent boost
(arrowhead) with H3N2 alone. (B) Numbers (average  SD) of H3N2-IgG ASC
precursors per 106 B lymphocytes found on week 30 in the spleens from two
groups of mice primed as inA. Results are from one experiment representative
of two, in which seven mice per group were analyzed. Asterisks indicate
statistically different values (*, P 0.05; **, P 0.01) between the two groups
of mice.
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rates, reaching background levels in both groups at  week 30.
Interestingly, after a boost with H3N2 alone given at week 30,
mice that received H3N2 plus GC in the first two immuniza-
tions developed significantly higher antibody titers than mice
that always received the protein alone (Fig. 5A). Consistent with
these results, we found that at week 30 (just before the boost) the
frequency of H3N2 antibody-secreting cell (ASC) precursors was
significantly higher in the spleen of mice immunized twice with
H3N2 plus GC than in the spleen of mice immunized twice with
H3N2 alone (Fig. 5B).
Collectively, these findings demonstrate that iNKT cell acti-
vation results in a higher antibody response to a recall immu-
nization because of an increased expansion of the antigen-
specific memory B cell pool.
Mechanisms of iNKT Cells Help Antibody Responses. We envisaged
that GC-activated iNKT cells could enhance antibody re-
sponses by influencing either the induction of antigen-specific
CD4 T cells, which are important to help antibody production,
or the differentiation of B cells to PCs, which are the cells that
do actually produce antibodies, or both. To address the first
point, WT and J18/ C57BL/6 mice were immunized once
with H3N2 or H3N2 plus GC, and killed 10 days later to assess
the capability of MHC-II-restricted CD4 T cells in their spleen
to produce IFN- and IL-4 in response to increasing doses of
H3N2 in vitro. We found that splenocytes from WT, and not
those from J18/ mice, secreted consistent amounts of cyto-
kines in response to H3N2 in vitro (Fig. 6A). Notably, only
splenocytes from WT mice immunized with H3N2 plus GC
produced high amount of IL-4 (Fig. 6A Right), which demon-
strates that aGC-activated iNKT cells potentiate the generation
of antigen-specific CD4 T cells after vaccination.
To determine the effects of aGC-activated iNKT cells on the
generation of antigen-specific PCs, we immunizedWT and J18/
mice twice with TT or TT plus GC. Eight weeks after the second
immunization, frequencies of specific PCs in the BM of immunized
micewere determined by aTT-specific-IgGELISPOTassay ex vivo.
We found detectable numbers of TT-specific IgG producing PCs
only in mice immunized with TT plus GC, whereas mice immu-
nized with TT alone had no detectable TT-specific PCs in their BM
(Fig. 6B). This finding demonstrates a key effect of aGC-activated
iNKT cells on PC generation and/or survival.
To address the role of cytokines in iNKT cells’ help to B cells, we
analyzed the adjuvant effect of GC in C57BL/6 WT mice and
congenic mice lacking IL-4 or the receptor for IFN- (IFN-R).
Fig. 6CLeft shows that inWTmice immunization withH3N2 alone
induced a Th2 response as indicated by the presence of IgG1 in the
absence of IgG2a, whereas immunization with H3N2 plus GC
elicited a Th0 response with both IgG1 and IgG2a. Mice lacking
IL-4 did not develop any antibody response when immunized with
H3N2 alone, whereas when immunized with H3N2 plus GC they
mounted a Th0 response, although with an inverted ratio between
IgG1 and IgG2a with respect to their WT littermates (Fig. 6C
Center). Mice lacking IFN-R (Fig. 6C Right), although unable to
produce IgG2a antibodies, after immunization with H3N2 plus
GC displayed significantly higher IgG1 titers than mice immu-
nized withH3N2 alone. Altogether, these findings suggest that IL-4
can be replaced by other cytokines (e.g., IL-13) to obtain the
Th2-like component of GC-dependent iNKT cells’ help to B
lymphocytes, while IFN- is essential for the Th1-like component
of the iNKT cell effector function and therefore for a balanced Th0
helper effect of iNKT cells.
Finally, we asked whether CD40/CD40L interactions were
required for the GC-dependent iNKT cell help in vivo. We
therefore assessed antibody responses to H3N2 in mice treated
with a neutralizing anti-CD40L mAb. As shown in Fig. 6D, after
immunization with H3N2 plus GC, mice treated with the
anti-CD40L mAb displayed significantly lower H3N2-specific
antibody titers than mice treated with control IgG.
Discussion
We have shown that immunization with proteins and GC
activates iNKT cells to help protein-specific B cells to produce
Fig. 6. CD40/CD40L interactions are required for iNKT cell help to antibody responses, whereas IL-4 and IFN-R are dispensable. (A) IFN- and IL-4 released in
response to H3N2 in vitro by splenocytes obtained from WT and J18/ C57BL/6 injected with PBS, H3N2, or H3N2 plus GC. Shown are average values (SD)
obtained by analyzing three mice per group. (B) Numbers (average SD) of PCs producing TT-specific IgG in the BM from WT and J18/ C57BL/6 mice (six mice
per group) 8 weeks after the second immunization with TT alone or TT plus GC. (C) IgG1/IgG2a subclass distribution of H3N2-specific serum antibodies in WT
C57BL/6 mice or in congenic mice lacking either IL-4 (IL-4/) or the IFN-R (IFN-R/), 2 weeks after two immunizations with H3N2 or H3N2 plus GC. Shown
are GMTs with 95% C.I. obtained analyzing three mice per group. (D) GMTs with 95% C.I. of H3N2-specific antibodies found on day 14 in sera from C57BL/6 WT
mice (five mice per group) treated on days 1, 0, and 1 with saturating amounts of a neutralizing anti-CD40L mAb or control IgG and immunized on day 0
with H3N2 plus GC. Results from one experiment representative of two are shown. Asterisks indicate statistically different values (*, P  0.05; **, P  0.01)
between groups of mice of the same genetic background immunized with the protein alone or the protein plus GC.
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antibodies. This adjuvant effect leads not only to increased
primary and memory antibody responses, but also to protective
immunity against pathogens. Furthermore, GC induces anti-
body titers as high as those obtained by classical adjuvants. Our
results represents a substantial increase of what is known about
the adjuvant activity of GC-activated iNKT cells (33, 42) and
clarifies crucial aspects of the interaction between NKT and B
cells by providing clues on the role played by iNKT cells in
regulating critical features of the adaptive antibody response,
such as protection from infections and generation of the memory
B cell pool. Depending on the cytokine pattern they promote,
adjuvants can be categorized as Th1 (e.g., CpG) or Th2 (e.g.,
Alum) and in mice this pattern correlates with the prevalent
production of antibodies of the IgG2a and IgG1 isotype, respec-
tively. GC does not polarize the Th response, rather it elicits a
balanced Th0 production of IgG1 and IgG2a antibodies.
Although hyporesponsiveness of iNKT cells has been reported
for a second systemic injection of high doses of GC in mice (37,
38), we did not observe a similar phenomenon after two immu-
nizations with protein antigens and GC. The lack of iNKT cell
hyporesponsiveness in our model could be related to either the
dose of injected GC or its route of administration. The dose of
GC we used (0.1 g) is 2- to 20-fold lower then those used to
induce iNKT cells anergy (37, 38). Indeed, it has been reported
that after two systemic injections of 0.2 g of GC, the in vitro
production of IL-4 by iNKT cells is unaffected, whereas the
production of IFN- is reduced only 2-fold (37), suggesting that
the iNKT cell hyporesponsiveness phenomenon is dose-
dependent. The route of administration of GC used in the
present work (i.m. or s.c.) is different from the one (i.p.) reported
to induce anergy in iNKT cells (37, 38), and it might provide a
slower distribution of the compound as compared with systemic
injection, possibly resulting in a milder activation of iNKT cells
and no subsequent hyporesponsiveness.
Efficient CD4 T cell help to B cells requires cognate
interaction and bystander stimuli such as CD40 engagement
and cytokines. INKT cell help to B cells in vivo also depends
on CD40L-CD40 interaction, as demonstrated by the reduc-
tion of antibody responses to proteins and GC in the presence
of neutralizing anti-CD40L antibodies. iNKT cells can help B
cells in mice lacking either IL-4 or IFN-R. However, these
KO mice mount antibody responses that are quantitatively
normal but qualitatively deficient in the IgG isotype specifi-
cally induced by either cytokine. Indeed, in the absence of
IL-4, immunization with protein and GC results in an in-
versed polarization, with a predominance of Th1-associated
antibodies (IgG2a) and a lower Th2 response (IgG1). In mice
lacking the IFN-R, polarization is more dramatic as IgG2a
antibodies are undetectable while IgG1 antibodies are nor-
mally induced.
These results are consistent with those obtained in the same
KO mice after different antigenic challenges (43, 44) and
indicate that iNKT cells provide help to B cells through the
combined action of CD40–CD40L interactions and cytokines.
GC-activated iNKT cells elicit a stronger CD4 T cell
response against the coadministered protein antigen, suggest-
ing that their adjuvant effect on the antibody response is also
related to an increased availability of MHC-II restricted T cell
help to B cells (28, 29). We have confirmed that in mice
knockout for MHC class II, due to the absence of conventional
CD4 Th cells, there is no B cell response toward T-dependent
antigens admixed with conventional adjuvants such as alum
(45). Remarkably, MHC II/ mice vaccinated with a protein
antigen and GC, have detectable levels of protein-specific
IgG, demonstrating that iNKT cells can, at least in part,
replace conventional CD4 Th functions.
In mice lacking iNKT cells, effector antibody responses after
two protein immunizations are similar to those observed in
WT mice, demonstrating that the absence of these cells does
not inf luence the amount of antibodies produced at the peak
of the immune response. Interestingly, in mice genetically
lacking iNKT cells we have observed a significant decrease in
the duration of serum antibody titers elicited by protein
vaccination as compared with WT mice. Since 8 weeks after
the second immunization (when levels of antigen-specific Ig
titers starts to diverge between WT and J18/ mice) the
number of antigen-specific PCs in the BM is below the
detection limit of ELISPOT assays, we could not formally
prove the relation between iNKT cells and PCs. However, we
have assessed PC frequency in WT mice immunized with
proteins and aGC and found an increased frequency of
BM-resident specific PCs. Therefore, it is likely that PC
survival, which is the most relevant parameter accounting for
serological memory in mice (41), is under the inf luence of a
spontaneous homeostatic activity of iNKT cells, possibly trig-
gered by the recognition of an endogenous glycolipid, such as
iGB3 (18, 20). Further experiments are warranted to formally
clarify the mechanisms underlying the spontaneous iNKT cell
help to serological memory.
Taken together, our results underscore the relevance of the
interplay between innate and adaptive effectors for the devel-
opment of efficient antibody responses and reveal iNKT cells
as players involved in this interaction.
Methods
Mice and Protocols for Experiments in Vivo. Mice. WT CD1 and
C57BL/6 mice were from Charles River (Calco, Italy). WT
BALB/c, C3H/HeJ, B6.129P2-Il4tm1Cgn/J IL-4-deficient (44),
and B6.129S7-Ifngtm1Ts/J IFN-R-deficient (43) mice were
from Jackson Laboratories (Bar Harbor, ME). B6.129-Tcra-
Jtm1Tg mice J18-deficient (46) and B6.129-CD1tm1Gru
CD1d-deficient mice (47) were kindly obtained from M.
Taniguchi (RIKEN, Yokohama, Japan) and H. R. MacDonald
(Ludwig Institute for Cancer Research, Lausanne, Switzer-
land) respectively, and were backcrossed 12 times onto
C57BL/6 at the San Raffaele Scientific Institute. B6.129S2-
Igh-6tm1Cgn MHC-II-deficient (AB0, referred to as MHC-
II/) (48), were from the European Mouse Mutant Archive
(Orleans, France).
Immunization. TT (0.1–10 g per dose), DT (3 g per dose), and
H3N2 andH1N1 (3 g per dose, from the human influenza viruses
A/Panama/2007/99 and A/New Caledonia/20/99, respectively) were
from Novartis Vaccines. Unless specified otherwise, immunization
were performed on days 0 and 15, and groups of 3–10 mice, 6–8
weeks old, were injected i.m. with antigens in 50 l of PBS alone or
withGC(0.1g per dose;Alexis, Lausen, Switzerland),Alum (0.1
mg/dose, Pierce, Rockford, IL), MF59 (50%; Novartis Vaccines),
CpG (25 g per dose; 5-tccatgacgttcctgacgtt-3; Primm, Milan,
Italy), or 50% complete Freund’s adjuvant/incomplete Freund’s
adjuvant. To block in vivoCD40–CD40L interactions, 400g of the
MR1 antiCD40LmAb (Taconic EuropeA/S, Ejby, Denmark) were
given i.p. at days 1, 0, and 1.
Influenza infection. Two weeks after the second immunization with
H1N1 alone, H1N1 plus GC, or H1N1 plus MF59, 10 mice per
group were challenged intranasally with 10 l of PBS containing
100 LD50 of the influenza virus A/WS/33(H1N1). Animal sur-
vival was assessed daily for 14 days. Mice were housed and
treated according to procedures reviewed and approved by the
Animal Ethical Committees of our institutes.
Measurement of Antigen-Specific Antibody Titers, PCs, and Memory B
Cell Frequencies. Circulating antigen-specific antibodies were
titrated by endpoint ELISA. Serial 1:3 dilution of sera was
plated onto ELISA plates (Nunc, Roskilde, Denmark) coated
with each given antigen. Bound antibodies were detected with
alkaline phosphatase-conjugated goat anti-mouse IgGAM
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(HL),IgG, IgG1, IgG2a, or IgG2c (Southern Biotechnology
Associates, Birmingham, AL), followed by the pNPP substrate
(Sigma/Aldrich, St. Louis, MO). Antibody titers are expressed
as reciprocal dilutions giving an OD405  mean blank OD405
plus 3 SD. Blanks consistently displayed OD405  0.1 and
10% variability.
The frequency of PCs in the BM fromWT and J18/mice
(five mice per group) was determined 8 weeks after the second
immunization with TT or TT and GC. Single-cell suspensions
were incubated overnight at 2 106 per well, in RPMI medium
1640 (Gibco/Life Sciences, Carlsbad, CA) 5% FCS (HyClone,
Logan, UT), into TT-coated MultiScreenHTS ELISPOT plates
(Millipore, Milan, Italy). Spots were revealed with an HRP-
conjugated goat-anti-mouse IgG antiserum followed by the
AEC substrate (Sigma/Aldrich) and enumerated by using
computer-assisted video image analysis Axioplan 2 (Zeiss,
Thornwood, NY).
ASC precursor frequencies were determined by culturing
splenocytes in limiting dilution as described (49). Eight rep-
licates for each cell dilution were plated into 96-well plates in
0.2 ml of RPMI medium 1640, 5% FCS  CpG (5 g/ml;
Primm, Milan, Italy) and IL-2 (1,000 units/ml; Novartis).
Antigen-specific IgGs in 10-day supernatants were detected by
ELISA as described above. The splenocyte dilution containing
one H3N2-ASC precursor was determined by applying the
Reed and Muench formula (50) to the distribution of wells,
giving an OD405 higher than the mean blank OD405 plus 3 SD.
Frequencies of preexisting H3N2-specific ASC in the spleen
were 2/106 B cells.
Antigen-Specific Cytokine Production in Vitro. Splenocytes were
obtained from WT and J18/ mice (three mice per group)
10 days after a single s.c. injection of PBS, H3N2, or H3N2 and
GC, and were cultured in duplicate, at 2 106 per well, in 0.2
ml of RPMI medium 1640, 5% FCS, and 0–2 g of H3N2.
IFN- and IL-4 in 48-h supernatants were measured by ELISA
(BD Pharmingen).
Statistics. For statistical analysis antibody titers were log10-
transformed and tested for normal distribution by using the
Kolmogorov–Smirnov test for continuous variables. Geometric
mean antibody titers (GMTs) and the 95% C.I. were derived
from the anti-log10 of the mean, and of the mean  SD, of the
log10 titer transformations. Comparisons between two groups
were done with the two-tailed Student t test for unpaired
samples, applying correction for unequal variances when re-
quired. Multiple comparisons were done by ANOVA with the
LSD correction. Survival rates after f lu challenge were com-
pared with the Mann–WhitneyU test (two-tailed). For all tests,
a value of P  0.05 was considered significant.
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